← Browse by Condition Medical Condition
paroxysmal nocturnal hemoglobinuria pnh
Trial Phases
Phase 2, Phase 3, Phase 1, Phase 2, Phase 1
ClinicalMetric tracks all active clinical trials for paroxysmal nocturnal hemoglobinuria pnh sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.
Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.
Frequently Asked Questions — paroxysmal nocturnal hemoglobinuria pnh Clinical Trials
How many clinical trials are currently recruiting for paroxysmal nocturnal hemoglobinuria pnh?
ClinicalMetric currently tracks 5 actively recruiting clinical trials for paroxysmal nocturnal hemoglobinuria pnh, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 5. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for paroxysmal nocturnal hemoglobinuria pnh?
paroxysmal nocturnal hemoglobinuria pnh research spans Phase 1 (2 trials), Phase 2 (3 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a paroxysmal nocturnal hemoglobinuria pnh clinical trial?
Eligibility criteria for paroxysmal nocturnal hemoglobinuria pnh trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Top Sponsors
Wuhan Createrna Science and Technology Co., Ltd 1 trial
Institute of Hematology & Blood Diseases Hospital, China 1 trial
Regeneron Pharmaceuticals 1 trial
Haisco Pharmaceutical Group Co., Ltd. 1 trial
Apellis Pharmaceuticals, Inc. 1 trial
Recruiting Clinical Trials
NCT06933914 Phase 2, Phase 3
Recruiting
Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria
Sponsor
Wuhan Createrna Science and Te...
View Trial → NCT04645199
Recruiting
National Longitudinal Cohort of Hematological Diseases
Sponsor
Institute of Hematology & Bloo...
View Trial → NCT07187401 Phase 1, Phase 2
Recruiting
A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 Inhibitor
Location
Canada, South Korea,...
Sponsor
Regeneron Pharmaceuticals
View Trial → NCT07152288 Phase 1
Recruiting
Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HSK39297 in Subjects With Hepatic Impairment
Sponsor
Haisco Pharmaceutical Group Co...
View Trial → NCT04901936 Phase 2
Recruiting
A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Location
United States, Czech...
Sponsor
Apellis Pharmaceuticals, Inc.
View Trial → ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional.
Full Disclaimer ·
Last Reviewed: November 2026 ·
Data Methodology